key: cord-0714285-epge0hf1 authors: Bansal, Naveen; Raturi, Manish; Bansal, Yashik title: SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward date: 2021-12-29 journal: Transfus Clin Biol DOI: 10.1016/j.tracli.2021.12.006 sha: 5d11d2d00c9fd671b8ee7b4d5b4de22dc445361c doc_id: 714285 cord_uid: epge0hf1 nan Author declares no conflict of interest. Since the first case of coronavirus disease 2019 in November 2019, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has undergone continuous evolution as a result of various mutations. These mutations have resulted in the production of variants of concern such as B. All these variants have one thing in common; all of them have multiple mutations as compared to the wild type of SARS-CoV-2. It has emerged that COVID-19 patients who are immunocompromised may be a source of these variants [1] . There is evidence that B.1.1.7 (alpha) variant which was first detected in the United Kingdom may have evolved from an immunocompromised host [1, 2] . Most recently, there is concern that B.1.1.529 variant may also have originated from an immunocompromised host [3] . It is now known that COVID-19 patients with immunodeficiency have a defective viral clearance and are at an increased risk of developing a chronic prolonged phase of infection [4] . Immunocompromised patients are unable to mount an immune response against the SARS-CoV-2 and therefore are ideal candidates for the administration of passive antibody therapy against SARS-CoV-2 [5] . Numerous case reports/-series have analyzed the safety and clinical efficacy of COVID-19 convalescent plasma (CCP) in immunocompromised COVID-19 patients and are available in the literature [6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17] . Notably, in many of these reports, CCP therapy was initiated late in the course of COVID-19, still, it resulted in rapid symptomatic improvement in the patients [6, 8, 9, 10, 13, 14, 15, 16] . CCP appears to be particularly effective in patients with B-cell lymphoproliferative disorders. In It is argued that CCP in immunocompromised COVID-19 patients can lead to the generation of SARS-CoV-2 variants due to multiple mutations during the prolonged phase of infection [18] . We did a literature search and found 8 case reports/ series which analyzed the evolution and subsequent mutations in SARS-CoV-2 in chronically infected immunocompromised patients [4, 19, 20, 21, 22, 23, 24, 25, 26] . The findings of these studies are summarised [ Table 1 ]. Out of these, CCP was used in the management of the patients in five studies, monoclonal antibodies (mAbs) in one study and neither of these in two studies. Notably, multiple mutations were seen in all cases irrespective of the use of CCP in the management of these More recently, neutralizing mAbs target the spike protein have also become available [27]. These mAbs contain a fixed amount of high titre neutralizing antibodies, whereas, in the case of CCP, the titre is variable from one unit to another. Therefore, as compared to CCP, neutralizing mAbs have the advantage that their dose can be standardised Both CCP and mAbs are effective tools in the management of immunocompromised COVID- Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert! Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with A look-back at convalescent plasma to treat COVID-19 Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report Treatment of immunocompromised COVID-19 patients with convalescent plasma Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report SARS-CoV-2 convalescent plasma 12 Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19 A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma COVID-19 convalescent plasma as long-term therapy in immunodeficient patients Convalescent plasma therapy for B-celldepleted patients with protracted COVID-19 Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. mSphere